Form 4: ZVRA CMO Reports Equity Grants and Share Sale

ZEVRA THERAPEUTICS' Chief Medical Officer, Adrian W. Quartel, reported new equity grants and a sale of common stock.

Summary

• Adrian W. Quartel, Chief Medical Officer of ZEVRA THERAPEUTICS, INC. (ZVRA), reported several transactions.
• Acquired 11,333 shares of common stock on January 30, 2026, through the vesting and settlement of restricted stock units.
• Disposed of 4,533 shares of common stock on January 30, 2026, at a weighted average price of $8.8321 per share, as part of a pre-arranged 10b5-1(c) plan adopted on March 26, 2025.
• Received a grant of 37,500 Restricted Stock Units (RSUs) on January 29, 2026, which will vest in installments starting January 29, 2027.
• Received a grant of 75,000 stock options on January 29, 2026, with an exercise price of $8.86, vesting in four equal annual installments beginning on the first anniversary of the grant date.
• Following these transactions, Quartel beneficially owns 9,723 shares of common stock, 37,500 Restricted Stock Units, and 75,000 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine executive compensation and a pre-planned sale, which are standard operational activities. The grants of new equity incentives are positive for aligning management with long-term company performance.

Positives

• Grant of 37,500 Restricted Stock Units (RSUs) on January 29, 2026, aligning executive interests with long-term company performance.
• Grant of 75,000 stock options on January 29, 2026, with an exercise price of $8.86, providing further incentive for value creation.

Negatives

• Sale of 4,533 shares of common stock at a weighted average price of $8.8321, reducing direct beneficial ownership of common stock.

Future Outlook

The newly granted 37,500 Restricted Stock Units will vest and settle in installments, with one-third vesting on January 29, 2027, and the remainder in equal annual installments thereafter, contingent on continued service. The 75,000 stock options will vest and become exercisable in four equal annual installments, beginning on the first anniversary of the grant date, also subject to continued service.

Industry Context

StockSavvy.ai notes that executive compensation through equity grants, such as Restricted Stock Units and stock options, is a standard practice in the biotechnology and pharmaceutical industry. This approach aims to align management interests with shareholder value and incentivize long-term performance and retention.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity grants with multi-year vesting schedules is typical for executive compensation in the biotech sector, comparable to practices at companies like Biogen or Gilead Sciences, which use similar long-term incentive plans to retain talent and drive innovation.
• The adoption of a 10b5-1(c) plan for share sales is a common practice among executives to manage personal liquidity and avoid accusations of trading on material non-public information, aligning with corporate governance best practices seen across the industry.

Stakeholder Impact

• Shareholders: Potential future dilution from the settlement of RSUs and exercise of stock options, balanced by increased alignment of executive interests with long-term company performance.
• Employees (specifically Adrian W. Quartel): Enhanced long-term incentives and increased equity stake in the company, contingent on continued service.

Next Steps

• Future vesting of 37,500 Restricted Stock Units on January 29, 2027, and subsequent annual installments.
• Future vesting of 75,000 stock options in four equal annual installments, beginning on the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 details routine insider transactions, including the vesting and sale of shares under a 10b5-1 plan, alongside new equity grants. These actions are typical for executive compensation and do not provide new fundamental information to warrant a change in investment thesis. The grants of new RSUs and stock options align management incentives with long-term company performance, which is a positive, but the sale of a portion of vested shares is also a common practice for liquidity or tax purposes. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to alter an existing position.

Keywords

ZEVRA THERAPEUTICS, ZVRA, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Adrian W. Quartel